A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer

NCT04843215 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 950

Last updated 2021-05-10

No results posted yet for this study

Summary

This is a phase III, multicenter, prospective, randomized, controlled clinical trial to evaluate the impact of omentectomy for advanced gastric cancer on patient survival.

Conditions

Interventions

PROCEDURE

Type of omentectomy

Experimental group D2 radical gastrectomy with partial omentectomy. Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    collaborator OTHER
  • Shanghai Zhongshan Hospital

    collaborator OTHER
  • Fujian Cancer Hospital

    collaborator OTHER_GOV
  • Fujian Medical University Union Hospital

    collaborator OTHER
  • First Affiliated Hospital of Guangxi Medical University

    collaborator OTHER
  • Harbin Medical University

    collaborator OTHER
  • Hebei Medical University Fourth Hospital

    collaborator OTHER
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER
  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER
  • Changzhi People's Hospital

    collaborator OTHER
  • The First Affiliated Hospital of Air Force Medicial University

    collaborator OTHER
  • First Affiliated Hospital of Kunming Medical University

    collaborator OTHER
  • LanZhou University

    collaborator OTHER
  • Liaoning Cancer Hospital & Institute

    collaborator OTHER
  • The First Affiliated Hospital of Nanchang University

    collaborator OTHER
  • Shandong Provincial Hospital

    collaborator OTHER_GOV
  • West China Hospital

    collaborator OTHER
  • Xinjiang Medical University Cancer Hospital

    collaborator UNKNOWN
  • Zhejiang Cancer Hospital

    collaborator OTHER
  • Chinese PLA General Hospital

    collaborator OTHER
  • Sun Yat-sen University Cancer Hosptial

    collaborator UNKNOWN
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    collaborator OTHER
  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04843215 on ClinicalTrials.gov